July 22-24, 2026 | Shanghai
Dr. Alex Zhavoronkov, Founder and Co-CEO of Insilico Medicine, and Dr. Feng Ren, Co-CEO and Chief Scientific Officer, have been invited to attend the inaugural China Pioneer Innovative Drug Global Congress (CPIC 2026) , which will grandly convene at the National Exhibition and Convention Center (Shanghai) from July 22 to 24. During this premier event, the two industry leaders will appear at several high-profile forums to deliver keynote speeches, sharing deep insights on how cutting-edge AI combines with "China Speed" to decode the mysteries of life and reshape the global drug R&D landscape.
July 23 | 14:30 - 14:50
Sub-Forum: Breaking Through in Global Drug R&D and the Commercialization of Innovative Drugs
Topic: AI-Driven Drug Discovery: The Global Landscape and Insilico Medicine’s Approach
Speaker: Dr. Alex Zhavoronkov, Founder and Co-CEO of Insilico Medicine
Dr. Alex Zhavoronkov will conduct a deep-dive analysis of Insilico Medicine’s unique, differentiated path to breaking through industry bottlenecks. He will showcase how Insilico leverages its proprietary triad—the end-to-end Pharma.AI platform, the MMAI Gym specialized training and benchmarking framework, and the fully automated Robotic Chemistry and Biology Laboratory —to reshape the fundamental logic of R&D, bypass prohibitive entry barriers, and achieve agile translation and closed-loop validation "from algorithm to clinical." Together with ecological partners, Insilico aims to embark on a new journey of AI-driven life sciences.
July 23 | 14:30 - 14:55
Sub-Forum: AI for Science Reshaping Innovative Drug R&D Session
Topic: From Technological Breakthroughs to Clinical Validation: The Second Half of AI-Driven Drug Development
Speaker: Dr. Feng Ren, Co-CEO and Chief Scientific Officer of Insilico Medicine
Dr. Feng Ren will dissect Insilico’s blueprint for "source innovation" in AI drug discovery. This journey spans from industry-leading intelligent target identification and disruptive de novo molecular generation to the cutting-edge integration of AI Agent technologies across the entire R&D pipeline. He will demonstrate how Insilico Medicine uses technology as a catalyst to continuously push and redefine the ultimate boundaries of AI-driven drug discovery.
About CPIC 2026 (Inaugural China Pioneer Innovative Drug Global Congress)
Positioned as the "best window" for international capital and multinational corporations to gain deep insights into China’s innovation ecosystem, and the "core hub" for Chinese biopharma companies to globalize and connect with the world, CPIC 2026 is poised to become the ultimate bellwether for healthcare investment and collaboration this year. The congress will host over 60 specialized sessions, covering a wide range of hot-button topics and future directions, including innovative drug R&D, cross-border licensing (BD) transactions, capital empowerment, and global regulatory registration.